Rein Therapeutics Inc. (RNTX) — Financial statements
Income statement, balance sheet, and cash flow for Rein Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 11↓22.6% | 14↑356903.3% | 0.00↓77.8% | 0.02↑5.6% | 0.02 | |
| General & Administrative Expenses | 11↓21.4% | 14↑121974.5% | 0.01↑17.3% | 0.01↑0.9% | 0.01 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 11↓21.4% | 14↑121974.5% | 0.01↑17.3% | 0.01↑0.9% | 0.01 | |
| Other Expenses | -0.00↓100.0% | 37↑3986969.0% | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 22↓66.3% | 65↑399949.2% | 0.02↓41.1% | 0.03↑3.9% | 0.03 | |
| Total Costs & Expenses | 22↓66.3% | 65↑399949.2% | 0.02↓41.1% | 0.03↑3.9% | 0.03 | |
| Operating Results | ||||||
| Operating Income | -22↑66.3% | -65↓399949.2% | -0.02↑41.1% | -0.03↓3.9% | -0.03 | |
| Depreciation & Amortization | 0.00↓98.4% | 0.06↑52841.2% | 0.00↓29.6% | 0.00↑39.7% | 0.00 | |
| EBITDA | -22↑21.8% | -28↓184081.5% | -0.02↑44.6% | -0.03↓3.8% | -0.03 | |
| EBIT | -22↑22.0% | -28↓183063.9% | -0.02↑44.5% | -0.03↓3.9% | -0.03 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 0.40↑66566.7% | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00↓100.0% | 0.40↑66566.7% | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -37↓3986969.0% | -0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -29↓3681.5% | 0.80↑146958.8% | 0.00↑71.1% | 0.00↓27.9% | 0.00 | |
| Income Before Tax | -51↑21.3% | -64↓408697.4% | -0.02↑42.4% | -0.03↓4.5% | -0.03 | |
| Income Tax Expense | -0.71↑53.9% | -2 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -50↑20.5% | -63↓398883.0% | -0.02↑42.4% | -0.03↓4.5% | -0.03 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -50↑20.7% | -63↓399614.0% | -0.02↑42.4% | -0.03↓4.5% | -0.03 | |
| Bottom-Line Net Income | -50↑20.7% | -63↓399614.0% | -0.02↑42.4% | -0.03↓4.5% | -0.03 | |
| EPS (Basic) | -1.96↑44.2% | -3.51↓2.6% | -3.42↑43.2% | -6.02↓2.2% | -5.89 | |
| EPS (Diluted) | -1.96↑44.2% | -3.51↓2.6% | -3.42↑43.2% | -6.02↓2.2% | -5.89 | |
| Weighted Average Shares | 25↑41.8% | 18↑290.1% | 5↑1.3% | 5↑2.2% | 4 | |
| Weighted Average Diluted Shares | 25↑41.8% | 18↑290.1% | 5↑1.3% | 5↑2.2% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.